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Overexpression of Phospholipase A 2 Group IIA in
Esophageal Squamous Cell Carcinoma and Association with
Cyclooxygenase-2 Expression
Yan-Chun Zhai1,2&, Bin Dong3&, Wen-Qiang Wei4, Yan He1,2, Xin-Qing Li4, Robert
T Cormier5, Wei Wang1,2,6*, Fen Liu1,2*
Abstract
Background: Esophageal cancer is one of the most frequently occurring malignancies and the seventh leading
cause of cancer-related deaths in the world. The esophageal squamous cell carcinoma (ESCC) is the most common
histological type of esophageal cancer worldwide. Materials and Methods: Our goal in this study was to detect
phospholipase A2 Group IIA (PLA2G2A) and cyclooxygenase-2 (COX-2) immuno-expression in ESCC in a highrisk population in China. Results: Positive expression of PLA2G2A protein was observed in 57.2% (166/290) of
the cases, while COX-2 was found in 257 of 290 samples (88.6%), both PLA2G2A and COX-2 being expressed
in 153 cases (52.8%), with a significant agreement (Kappa=0.091, p=0.031).Overexpression of PLA2G2A was
significantly correlated with the depth of invasion (p=0.001). Co-expression of PLA2G2A and COX-2 not only
significantly correlated with the depth of invasion (p=0.004) but also with TNM stage (p=0.04). Conclusions:
Our results showed that in patients with ESCC, PLA2G2A overexpression and PLA2G2A co-expression with
COX-2 is significantly correlated with advanced stage. The biological role and pathophysiologic regulation of
PLA2G2A and COX-2 overexpression in ESCC deserve further investigation.
Keywords: Esophageal SCC - phospholipase A2 group IIA - cyclooxygenase-2 - immunohistochemistry
Asian Pac J Cancer Prev, 15 (21), 9417-9421

Introduction
Esophageal cancer is a highly aggressive malignant
disease with a 5-year survival rate of 10% to 15% (Ferri
et al., 2012). The incidence of esophageal cancer varies
greatly between populations and across geographic
regions. The Taihangshan Mountain area, including
Linxian in Henan Province, a rural area of China, has
the highest incidence of esophageal cancer, especially
squamous cell carcinoma (ESCC), in the world (>100 per
100, 000 population) (Zhang et al., 2011; Lin et al., 2013).
Inflammation has been recognized as a contributing
factor for the pathogenesis of ESCC. There are
results showing that two key inflammatory enzymes,
Phospholipase A 2 Group IIA (PLA2G2A) and
cyclooxygenase-2 (COX-2) are involved in the pathways
of arachidonic acid (AA) biosynthesis, and both play an
important role in inflammation and angiogenesis as well
as cancer (Murakami et al., 2011). Recently, we reported
that PLA2G2A and COX-2 gene single nucleotide
polymorphisms (SNPs) may modify the risk of ESCC

development (Liu et al., 2014). However, the relationship
between PLA2G2A and COX-2 protein expression and
ESCC clinical features remains controversial in the
literature (Li et al., 2009;Ren et al., 2013). Moreover, a
correlation between the co-expression of PLA2G2A and
COX-2 in ESCC has not yet been reported.
The present study aimed to evaluate the relationship
between PLA2G2A and COX-2 expression in ESCC,
and to determine if co-occur between these two proteins
are correlated with a set of well-known clinical and
pathological features of esophageal carcinoma in a highrisk Chinese population.

Materials and Methods
Patients and tissue samples
This case-control study consecutively recruited a total
of 290 primary esophageal squamous cell carcinoma
patients, who underwent surgical resection of primary
ESCC at the Yaocun County hospital in Linxian, Henan
Province, China from October 2009 to September 2010.
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Lymph node status was determined through biopsy. Tumor
stage was determined according to the AJCC TNM criteria
(Edge et al., 2009), 38 cases were stage I, 137 cases
were stage II, 97 cases were stage III and 18 cases were
stage IV. The 290 cancerous and 30 paired noncancerous
tissues from these patients were routinely fixed in 10%
buffered formalin and blocked in paraffin, and embedded
in paraffin blocks for histological procedures and
immunohistochemical staining. None of the patients had
received chemo cancer therapy before surgery.
The study was approved by the Institutional Review
Board of Capital Medical University (Beijing, China), and
all subjects gave written informed consent.
Immunohistochemistry
Immunohistochemistry (IHC) was performed using
the streptavidin-biotin method. Four-micrometer-thick
sections of representative blocks from each case were
deparaffinized in xylene, rehydrated, and treated with 3%
hydrogen peroxide for 10 minutes to block endogenous
peroxidase activity. All sections were subjected to heatinduced epitope retrieval by autoclaving sections in a
10mM citrate buffer (pH6.0) for 10 minutes. After cooling
to room temperature, the sections were treated with 3%
hydrogen peroxide for 5 minutes followed by application
of the primary antibody and then incubated at 4°C
overnight. The antibodies used were rabbit anti-human
PLA2G2A polyclonal antibody (ab23705, 1:200; Abcam,
Cambridge, MA, USA) and mouse anti-human COX-2
monoclonal antibody (1:100; Cayman Chemical Co., Ann
Arbor, MI). The sections that were tested for PLA2G2A
and COX-2 IHC were incubated with polyperoxidaseanti-mouse/rabbit immunoglobulin (GBI) for 30 minutes
at 37°C, and antibody-binding sites were visualized by
DAB kit (Zhongshan Golden Bridge Co., Beijing, China).
Non-immune serum instead of the primary antibody was
used as negative control.
Evaluation of immunohistochemistry
The immunohistochemical expression of PLA2G2A
and COX-2 was examined independently by 2
pathologists. The percentage of positive cells was graded
semiquantitatively, and each sample was assigned to one
of the following categories: grade 1, <5% cells showed
immunoreactivity; grade 2, 5%-30% positive cells; and
grade 3, >30% positive cells. For final statistical analysis,
positive expression was defined as cells with grade 2 or
above (≥5%) expression levels.

Statistical analysis
All statistical analyses were performed using SPSS
software version 13.0 (SPSS Inc., Chicago, IL, USA).
The distribution between the expression of COX-2 or
PLA2G2A and the clinical and pathological features
of ESCC patients was evaluated using Chi-squared or
Fisher’s exact test. The agreement between expression
of COX-2 and PLA2G2A was assessed by consistency
test. The relationship between the two biomarkers coexpression and the clinical and pathological features of
patients was determined using Spearman’s rank order
correlation coefficients. Two sided significance tests
were used throughout, p≤0.05 was considered statistically
significant.

Results
Background of all patients is shown in Table 1. A
total of 290 patients, including 202 (69.7%) males and 88
(30.3%) females, were included in this study. The mean
age of patients was 59.46±7.95 years old.
PLA2G2A protein expression in primary esophageal
cancer
PLA2G2A protein expression in esophageal cancer
tumor specimens was determined by immunohistochemistry.
A)

B)

C)

Figure 1. Representative Immunostaining of COX2 and PLA2G2A in Esophageal Cancerous and
Noncancerous Tissues. A) Positive staining for PLA2G2A
in esophageal tumor tissues. B) Negative staining in normal
esophageal mucosa. C) Positive staining for COX-2 in
esophageal tumor tissues.Original magnifications ×400 (A, B
and C)

Table 1. Comparison of Characteristics in ESCC Patients from High-Risk Linxian County, China
Characteristics
N(%)
		

PLA2G2A n(%)		
p*
COX-2 n(%)		
Negative
Positive		 Negative
Positive

Gender

90(72.6)
34(27.4)
64(51.6)
60(48.4)
78(62.9)
46(37.1)
50(40.3)
74(59.7)

Age(years)
Smoking
Drinking
*Chi-squared test
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Male
Female
<60
≥60
Yes
No
Yes
No

202(69.7)
88(30.3)
143(49.3)
147(50.7)
181(62.4)
109(37.6)
107(36.9)
183(63.1)

112(67.5)
0.35
54(32.5)		
79(47.6)
0.49
87(52.4)		
103(62.0)
0.88
63(38.0)		
57(34.3)
0.29
109(65.7)		
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23(69.7)
10(30.3)
13(39.4)
20(60.6)
20(60.6)
13(39.4)
17(51.5)
16(48.5)

179(69.6)
78(30.4)
130(50.6)
127(49.4)
161(62.6)
96(37.4)
90(35.0)
167(65.0)

p*
0.99
0.23
0.82
0.06
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Table 2. Association of PLA2G2A and COX-2 Expression with Pathological Features in ESCC
Diagnosis		
N(%)
			
Differentiation

Well
Moderated
Poorly
Histological types
Intramucosal cancer
Invasive cancer
Depth of invasion
T1
T2
T3+ T4
Lymph node metastasis Negative
Positive
Metastasis
Negative
Positive
TNM stages
Ⅰ
Ⅱ
Ⅲ
Ⅳ

52(17.9)
140(48.3)
98(33.8)
10(3.4)
280(96.6)
47(16.2)
44(15.2)
199(68.6)
155(53.4)
135(46.6)
272(93.8)
18(6.2)
38(13.1)
137(47.2)
97(33.4)
18(6.3)

*Chi-squared or Fisher’s exact test.#Significant at the level of p<0.05

PLA2G2A n (%)		
p*
Negative
Positive		
18(14.5)
62(50.0)
44(35.5)
6(4.8)
118(95.2)
30(24.2)
12(9.7)
82(66.1)
71(57.3)
53(42.7)
115(92.7)
9(7.3)
23(18.5)
56(45.2)
36(29.0)
9(7.3)

Table 3. Relation between the Protein Expression of
COX-2 and PLA2G2A in ESCC
COX-2 expression

PLA2G2A expression n(%)

Kappa

p*

Positive
Negative		
n=166
n=124
		
Positive
153(59.5)
104(40.5)
0.091
0.03
Negative
13(39.4)
20(60.6)		

34(20.5)
0.42
78(47.0)		
54(32.5)		
4(2.4)
0.26
162(97.6)		
17(10.2)
0.001#
32(19.3)		
117(70.5)		
84(50.6)
0.26
82(49.4)		
157(94.6)
0.52
9(5.4)		
15(9.0)
0.08
81(48.8)		
61(36.7)		
9(5.4)		

COX-2 n (%)		
Negative
Positive
7(21.2)
13(39.4)
13(39.4)
2(6.1)
31(93.9)
9(27.3)
6(18.2)
18(54.5)
17(51.5)
16(48.5)
30(90.9)
3(9.1)
7(21.2)
12(36.4)
11(33.3)
3(9.1)

45(17.5)
127(49.4)
85(33.1)
8(3.1)
249(96.9)
38(14.8)
38(14.8)
181(70.4)
138(53.7)
119(46.3)
242(94.2)
15(5.8)
31(12.1)
125(48.6)
86(33.5)
15(5.8)

p*
0.56
0.38
0.13
0.81
0.47
0.38

Table 5. Comparison of Pathological Features between
the COX-2(+)/PLA2G2A(+) and all other Groups
Combined
Diagnosis
		
		

COX-2(+)/
Other groups
PLA2G2A(+)
(n=137), n(%)
group (n=153), n(%)

p*

Differentiation			0.86
Well
29 (19.0)
23 (16.8)
Moderated
74 (48.4)
66 (48.2)
Table 4. Comparison of Characteristics in ESCC
Poorly
50 (32.6)
48 (35.0)
Patients between the COX-2(+)/PLA2G2A(+) and all
Histological types			
0.41
100.0 Intramucosal cancer
4 (2.6)
6 (4.4)
other Groups Combined
Invasive6.3
cancer
131 (95.6)
10.1149 (97.4)
20.3
Characteristics COX-2 (+)/PLA2G2A (+)
Other groups
p*
Depth of invasion			
0.004#
group (n=153), n (%)
(n=137), n (%)
T1
16 (10.5)
31 (22.6)
25.0
30 (19.6)
14 (10.2)
Gender Male
101 (66.0)
101 (73.8)
0.15 75.0 T2
T3+T4
107 (69.9)
92 (67.2)
Female
52 (34.0)
36 (26.2)
Lymph
node			
0.37
46.8
Age
<60
72 (47.1)
71 (51.8)
0.42
56.3
metastasis
≥60
81 (52.9)
66 (48.2)
78 (51.0)
77 (56.2)
54.2
Smoking Yes
92(60.1)
89(65.0)
0.39 50.0 Negative
31.3
Positive
75 (49.0)
60 (43.8)
No
61(39.9
48(35.0)
Metastasis			0.09
Drinking Yes
49(32.0)
58(42.3)
0.07
Negative
147(54.0)
125(46.0)
No
104(68.0)
79(57.7)
Positive
6(33.3)
12(66.7)
*Chi-squared test
25.0TNM stages			
0.04#
38.0
Ⅰ
14 (9.2)
24 (17.5)
31.3
31.3
23.7
As shown in Figure 1A, PLA2G2A immunoreactivity
Ⅱ
77 (50.3)
60 (43.7)
Ⅲ
56 (36.6)
41 (30.0)
was localized mainly in the cytoplasm. The intensity of
6 (3.9)
12 (8.8)
PLA2G2A staining was remarkably higher in primary 0 Ⅳ
*Consistency test, Significant at the level of p<0.05

COX-2 protein expression in primary esophageal cancer
COX-2 protein expression in esophageal cancer tumour
specimens was also determined by immunohistochemistry.
As shown in Figure 1C, COX-2 immunoreactivity was
also localized mainly in the cytoplasm. The intensity
of COX-2 staining was remarkably higher in primary

esophageal carcinoma than in matched normal mucosa,
high levels of COX-2 expression were found in 257 of
290 (88.6%) cancers and 3 of 30 (10.0%) non-cancerous
tissues (p<0.001).
There was no significant correlation between
the expression rate of COX-2 with the clinical and
pathological features in ESCC (Table 2).
Co-expression of PLA2G2A and COX-2 in ESCC
To determine the degree of co-expression of PLA2G2A
and COX-2 in ESCC, we divided the 290 patients into
4 groups: (1) PLA2G2A and COX-2 positive group
[PLA2G2A (+)/COX-2 (+) group], n=153 (52.7%); (2)
PLA2G2A positive only group [PLA2G2A (+)/COX-2
(-) group], n=13 (4.5%); (3) COX-2 positive only group
[PLA2G2A (-)/COX-2 (+) group], n=104 (35.9%); and (4)
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30.0

5
30.0

30.0

None

Remission

Persistence or recurrence

Newly diagnosed with treatment

*Chi-squared or Fisher’s exact test.#Significant at the level of p<0.05.

Newly diagnosed without treatment

esophageal carcinoma than in matched normal mucosa
(Figure 1B), which nearly had absent staining. Prevalence
of PLA2G2A expression positivity was found in 166 of
290 (57.2%) cancers and 1 of 30 (3.3%) non-cancerous
tissues (p<0.001).
Moreover, increased immunoreactivity of PLA2G2A
in advanced tumor invasion was also observed (p=0.001).
No significant correlation between PLA2G2A expression
was observed for the degree of tumor differentiation,
histological types, T class, lymph node metastasis or tumor
stage in this case-control study (Table 2).

1
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both PLA2G2A and COX-2 negative group [PLA2G2A
(-)/COX-2 (-) group], n=20 (6.9%). We found a significant
co-expression of PLA2G2A and COX-2 (Kappa=0.09,
p=0.03) (Table 3).
Further, we divided the 290 patients into another 2
sub-groups: the (PLA2G2A (+)/COX-2 (+) group and the
other three groups combined.The clinical background of
these 2 groups is provided in Table 4. We found that the
PLA2G2A (+)/COX-2 (+) group was significantly more
advanced with regard to the depth of invasion (p=0.004)
and TNM stage (p=0.04) (Table 5), compared with the
other three combined groups.

Discussion
Previous studies have shown that the incidence of
esophageal chronic inflammation is very high in high-risk
populations for esophageal cancer, and that the mortality
of ESCC is closely related with the high incidence of
chronic inflammation (Savage et al., 2004; Liu et al.,
2014). Thus, it suggested that chronic inflammation
may be an important precancerous esophageal lesion. In
the present study, we investigated the expression of the
inflammatory proteins PLA2G2A and COX-2 in ESCC
patients; in particular we examined the correlation of
these two biomarkers with clinical and pathological data,
in order to determine if the dysregulation of the proteins
could be associated with ESCC.
Our results showed a moderate increase (57.2%)
in PLA2G2A expression in ESCC, and PLA2G2A
overexpression in ESCC correlated with greater mucosa
invasion potential (p=0.001), which is contrary to at least
one other report (Ren et al., 2013). Although the reasons
for this difference remain to be elucidated, dysregulation
of the PLA2G2A protein might cause carcinogenesis
through multiple mechanisms (Jiang et al., 2002; Fijneman
et al., 2008; Wang et al., 2013). The pro-tumorigenic (e.g.,
prostate cancer (Jiang et al., 2002; Graham et al., 2008))
or anti-tumorigenic effects (e.g., gastric cancer (Leung et
al., 2002; Ganesan et al., 2008;Xing et al., 2011; Wang et
al., 2013)) of PLA2G2A appear to be tissue specific, as
well as in human intestinal cancer, the role of PLA2G2A
remains elusive. Several studies have reported both upand down-regulation of PLA2G2A expression in human
colorectal cancers (MacPhee et al., 1995; Cormier et al.,
1997; Cormier et al., 2000).
A few in vitro studies further demonstrated that
PLA2G2A expression induces the proliferation of human
astrocytoma and esophageal adenocarcinoma cells, and
treatment with specific PLA2G2A inhibitors or gene
knockdown attenuates tumor growth (Martin et al., 2009;
Mauchley et al., 2010). Consequently, PLA2G2A has been
proposed as a target for the treatment of human cancer
(Cummings, 2007; Scott et al., 2010).
COX-2 enzyme is one of the two isoforms of
cyclooxygenase (COX) producing prostaglandins from
arachidonic acid. COX-2 levels have been found to be
high in various tumors (Liu et al., 2006; Gomes et al.,
2013; Peng et al., 2013; Tabriz et al., 2013). This protein
has an important role in carcinogenesis by promoting
increased cell proliferation, reducing apoptosis and
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acting in angiogenesis (Takedo, 1998). Our results show
a significant increase (88.6%) in COX-2 expression in
ESCC, as previously reported (Gomes et al., 2013). We
found no significant correlation of COX-2 with tumor
data. However, both PLA2G2A (+)/COX-2 (+) group was
significantly more advanced with regard to the depth of
invasion (P=0.004) and TNM stage (p=0.04) (Table 5),
PLA2G2A and COX-2 co-occur with ESCC and that are
characterized by inflammation. These results suggested
that the activation of eicosanoid metabolic pathway is
one of the important predictive factors of esophageal
cancer. It has been known that disruption of the mouse
PLA2G2A, a potential source of AA for COX-2, increases
tumor number despite the fact that the mutation has been
predicted to decrease prostaglandin production (Hong KH,
et al., 2001). Some studies have suggested that PLA2G2A
and COX-2 play a role in other diseases (Galecki et al.,
2012).
Previously we have shown that functional SNPs
(rs11644) in the genes encoding PLA2G2A and COX2 (rs12042763) confer susceptibility to develop ESCC
(Liu et al., 2014). Therefore, one might conclude that
the increased expression for PLA2G2A and COX-2
established in the present study might be genotype
dependent. There is no evidence for a relation between the
PLA2G2A and COX-2 gene SNPs and expression (data
not shown). The variant might be in linkage disequilibrium
with other variants that affect expression. The expression
might also be related to another completely different
variant and increased expression might be circumstances.
The increased level of PLA2G2A and COX-2 in the ESCC
tissue might explain their effectiveness of non-steroid
anti-inflammatory drugs (NSAID) as prevention and
therapies for ESCC.
In summary, PLA2G2A and COX-2 might play
an important role in the progression of ESCC, as coexpression of PLA2G2A and COX-2 correlates with not
only the depth of invasion but also TNM stage. The precise
mechanisms underlying the risk effect of PLA2G2A and
COX-2 interaction on depth of invasion remain to be
elucidated in further cell- and population-based studies.
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